HEALEY ALS Trial Regimen I Expands to 240 Participants
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The decision to expand the trial is driven by higher than expected enrolment rates and aims to provide a more informative dataset without altering funding requirements. The company will host a webinar to discuss the trial's recruitment expansion and provide further details.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neurizon Therapeutics Limited on 6ix
In the deck
Earlier from Neurizon Therapeutics
- Ethics Approval Received for NUZ-001 Oral Liquid P1 Study
- Placement of Entitlement Offer Shortfall
- NUZ-001 Data Shows Multi-Pathway Protein Clearance
- Neurizon announces leadership transition
- Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
Later from Neurizon Therapeutics
- HEALEY ALS Platform Trial Regimen I expands to 240 participants
- HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule
- Neurizon executes long-term supply agreement with Elanco
- HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27
- HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics